Nuveen Asset Management LLC Takes $1.01 Million Position in Omnicell, Inc. (OMCL)

Nuveen Asset Management LLC bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,414 shares of the company’s stock, valued at approximately $1,005,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Meeder Asset Management Inc. bought a new stake in shares of Omnicell in the 4th quarter worth about $35,000. Bronfman E.L. Rothschild L.P. grew its position in shares of Omnicell by 451.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock valued at $38,000 after buying an additional 506 shares during the last quarter. IFP Advisors Inc grew its position in shares of Omnicell by 109.3% during the 4th quarter. IFP Advisors Inc now owns 741 shares of the company’s stock valued at $45,000 after buying an additional 387 shares during the last quarter. First Hawaiian Bank grew its position in shares of Omnicell by 121.2% during the 4th quarter. First Hawaiian Bank now owns 1,369 shares of the company’s stock valued at $84,000 after buying an additional 750 shares during the last quarter. Finally, Private Capital Group LLC grew its position in shares of Omnicell by 14.9% during the 4th quarter. Private Capital Group LLC now owns 1,390 shares of the company’s stock valued at $85,000 after buying an additional 180 shares during the last quarter. Institutional investors own 97.25% of the company’s stock.

OMCL has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, December 31st. BidaskClub lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, January 31st. Piper Jaffray Companies reissued a “neutral” rating and set a $70.00 target price on shares of Omnicell in a research note on Friday, February 8th. They noted that the move was a valuation call. Finally, ValuEngine raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Omnicell currently has a consensus rating of “Buy” and a consensus target price of $76.56.

Shares of NASDAQ:OMCL traded down $0.29 during trading on Friday, reaching $71.38. The company had a trading volume of 451,831 shares, compared to its average volume of 271,402. The company has a current ratio of 1.94, a quick ratio of 1.45 and a debt-to-equity ratio of 0.20. Omnicell, Inc. has a twelve month low of $42.01 and a twelve month high of $86.87. The firm has a market cap of $2.94 billion, a P/E ratio of 46.65, a P/E/G ratio of 3.32 and a beta of 1.23.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 7th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.16. Omnicell had a net margin of 4.79% and a return on equity of 9.31%. The business had revenue of $211.75 million for the quarter, compared to the consensus estimate of $215.41 million. During the same period in the previous year, the firm earned $0.55 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities research analysts forecast that Omnicell, Inc. will post 1.83 EPS for the current year.

In other news, CFO Peter J. Kuipers sold 1,044 shares of the business’s stock in a transaction that occurred on Saturday, March 9th. The shares were sold at an average price of $44.34, for a total transaction of $46,290.96. Following the sale, the chief financial officer now owns 56,873 shares in the company, valued at $2,521,748.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Dan S. Johnston sold 8,210 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $81.16, for a total transaction of $666,323.60. Following the completion of the transaction, the executive vice president now owns 36,504 shares in the company, valued at approximately $2,962,664.64. The disclosure for this sale can be found here. Insiders sold a total of 88,982 shares of company stock worth $7,389,181 over the last quarter. Insiders own 2.77% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Nuveen Asset Management LLC Takes $1.01 Million Position in Omnicell, Inc. (OMCL)” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/nuveen-asset-management-llc-invests-1-01-million-in-omnicell-inc-omcl.html.

Omnicell Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Recommended Story: Find a Trading Strategy That Works

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.